Conference abstract · 2018
Conference abstractPublished 26 Jun 2017
Biological and genetic factors associated to treatment resistance in aggressive B-cell lymphoma
The University of Texas MD Anderson Cancer Center, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Clinical heterogeneity is a major challenge for the treatment of diffuse large B cell lymphoma (DLBCL). Different cell-of-origin may contribute to the distinct biology of DLBCL as suggested by the germinal center-like and activated B cell (ABC)-like DLBCL classification system. Characterization of biological and genetic parameters underlying the molecular mechanisms help to identify critical targets responsible for drug resistance, treatment failure and recurrence, and it is helpful for better understanding the pathogenesis of DLBCL. In this presentation, the important molecular and biological events are systemically analyzed in a large cohort of de novo DLBCL patients to evaluate for the correlation of biological and genetic parameters with clinical outcome using high-throughput next generation sequencing (NGS). Gene expression and epigenetic miRNA profiling have also been explored for particular signature from each of the patients based on B-cell differentiation. Combined genetic, clinical and pathologic dissections provide insight in better understanding of the cell-of-origin, drug resistance, and recurrence in DLBCL patients.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 2012
Association of Caspase 8 and Caspase 10 Genetic Polymorphisms with B-cell Non Hodgkin's Lymphoma in Egypt: A Case-Control Study
Research article · 2012
SF1126, a Pan-PI3K Inhibitor has Potent Pre-Clinical Activity in Aggressive B-Cell Non-Hodgkin Lymphomas by Inducing Cell Cycle Arrest and Apoptosis
Commentary · 28 Jun 2023
Overcoming Immune Resistance in Diffuse Large B-Cell Lymphoma: Targeting Escape Mechanisms for Effective Immunotherapy
Conference abstract · 2018
Novel immunotherapies targeting BAFF-receptor for drug-resistant B-cell lymphoma and leukemia
More from this journal
The newest in Cancer Science & Therapy.
Commentary · 21 Feb 2026
Functional Immune Biomarker Identification in Patients with Breast Cancer
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Ken H Young”

